Matthew Golding
London Research Institute
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Matthew Golding.
Journal of Cell Biology | 2003
Holger Gerhardt; Matthew Golding; Marcus Fruttiger; Christiana Ruhrberg; Andrea Lundkvist; Alexandra Abramsson; Michael Jeltsch; Christopher A. Mitchell; Kari Alitalo; David T. Shima; Christer Betsholtz
Vascular endothelial growth factor (VEGF-A) is a major regulator of blood vessel formation and function. It controls several processes in endothelial cells, such as proliferation, survival, and migration, but it is not known how these are coordinately regulated to result in more complex morphogenetic events, such as tubular sprouting, fusion, and network formation. We show here that VEGF-A controls angiogenic sprouting in the early postnatal retina by guiding filopodial extension from specialized endothelial cells situated at the tips of the vascular sprouts. The tip cells respond to VEGF-A only by guided migration; the proliferative response to VEGF-A occurs in the sprout stalks. These two cellular responses are both mediated by agonistic activity of VEGF-A on VEGF receptor 2. Whereas tip cell migration depends on a gradient of VEGF-A, proliferation is regulated by its concentration. Thus, vessel patterning during retinal angiogenesis depends on the balance between two different qualities of the extracellular VEGF-A distribution, which regulate distinct cellular responses in defined populations of endothelial cells.
The EMBO Journal | 2002
Roman Nawroth; Gregor Poell; Alexander Ranft; Stephan Kloep; Ulrike Samulowitz; Gregor Fachinger; Matthew Golding; David T. Shima; Urban Deutsch; Dietmar Vestweber
VE‐cadherin is the essential adhesion molecule in endothelial adherens junctions, and the regulation of protein tyrosine phosphorylation is thought to be important for the control of adherens junction integrity. We show here that VE‐PTP (vascular endothelial protein tyrosine phosphatase), an endothelial receptor‐type phosphatase, co‐precipitates with VE‐cadherin, but not with β‐catenin, from cell lysates of transfected COS‐7 cells and of endothelial cells. Co‐precipitation of VE‐cadherin and VE‐PTP required the most membrane‐proximal extracellular domains of each protein. Expression of VE‐PTP in triple‐transfected COS‐7 cells and in CHO cells reversed the tyrosine phosphorylation of VE‐cadherin elicited by vascular endothelial growth factor receptor 2 (VEGFR‐2). Expression of VE‐PTP under an inducible promotor in CHO cells transfected with VE‐cadherin and VEGFR‐2 increased the VE‐cadherin‐mediated barrier integrity of a cellular monolayer. Surprisingly, a catalytically inactive mutant form of VE‐PTP had the same effect on VE‐cadherin phosphorylation and cell layer permeability. Thus, VE‐PTP is a transmembrane binding partner of VE‐cadherin that associates through an extracellular domain and reduces the tyrosine phosphorylation of VE‐cadherin and cell layer permeability independently of its enzymatic activity.
Proceedings of the National Academy of Sciences of the United States of America | 2010
Lynsey G. Bilsland; Erik Sahai; Gavin Kelly; Matthew Golding; Linda Greensmith; Giampietro Schiavo
ALS is a fatal neurodegenerative disease characterized by selective motor neuron death resulting in muscle paralysis. Mutations in superoxide dismutase 1 (SOD1) are responsible for a subset of familial cases of ALS. Although evidence from transgenic mice expressing human mutant SOD1G93A suggests that axonal transport defects may contribute to ALS pathogenesis, our understanding of how these relate to disease progression remains unclear. Using an in vivo assay that allows the characterization of axonal transport in single axons in the intact sciatic nerve, we have identified clear axonal transport deficits in presymptomatic mutant mice. An impairment of axonal retrograde transport may therefore represent one of the earliest axonal pathologies in SOD1G93A mice, which worsens at an early symptomatic stage. A deficit in axonal transport may therefore be a key pathogenic event in ALS and an early disease indicator of motor neuron degeneration.
The EMBO Journal | 2007
Enrico Magnani; Juan Fan; Laura Gasparini; Matthew Golding; Meredith Williams; Giampietro Schiavo; Michel Goedert; Linda A. Amos; Maria Grazia Spillantini
Tau is an axonal microtubule‐associated protein involved in microtubule assembly and stabilization. Mutations in Tau cause frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP‐17), and tau aggregates are present in Alzheimers disease and other tauopathies. The mechanisms leading from tau dysfunction to neurodegeneration are still debated. The dynein–activator complex dynactin has an essential role in axonal transport and mutations in its gene are associated with lower motor neuron disease. We show here for the first time that the N‐terminal projection domain of tau binds to the C‐terminus of the p150 subunit of the dynactin complex. Tau and dynactin show extensive colocalization, and the attachment of the dynactin complex to microtubules is enhanced by tau. Mutations of a conserved arginine residue in the N‐terminus of tau, found in patients with FTDP‐17, affect its binding to dynactin, which is abnormally distributed in the retinal ganglion cell axons of transgenic mice expressing human tau with a mutation in the microtubule‐binding domain. These findings, which suggest a direct involvement of tau in axonal transport, have implications for understanding the pathogenesis of tauopathies.
Developmental Biology | 2008
Quenten Schwarz; Kathryn E. Waimey; Matthew Golding; Hyota Takamatsu; Atsushi Kumanogoh; Hajime Fujisawa; Hwai Jong Cheng; Christiana Ruhrberg
In vertebrates, class 3 semaphorins (SEMA3) control axon behaviour by binding to neuronal cell surface receptors composed of a ligand binding subunit termed neuropilin (NRP) and a signal transduction subunit of the A-type plexin family (PLXNA). We have determined the requirement for SEMA3/NRP/PLXN signalling in the development of the facial nerve, which contains axons from two motor neuron populations, branchiomotor and visceromotor neurons. Loss of either SEMA3A/NRP1 or SEMA3F/NRP2 caused defasciculation and ectopic projection of facial branchiomotor axons. In contrast, facial visceromotor axons selectively required SEMA3A/NRP1. Thus, the greater superficial petrosal nerve was defasciculated, formed ectopic projections and failed to branch in its target area when either SEMA3A or NRP1 were lost. To examine which A-type plexin conveyed SEMA3/neuropilin signals during facial nerve development, we combined an expression analysis with loss of function studies. Even though all four A-type plexins were expressed in embryonic motor neurons, PLXNA1 and PLXNA2 were not essential for facial nerve development. In contrast, loss of PLXNA4 phenocopied the defects of SEMA3A and NRP1 mutants, and loss of PLXNA3 phenocopied the defects of SEMA3F and NRP2 mutants. The combined loss of PLXNA3 and PLXNA4 impaired facial branchiomotor axon guidance more severely than loss of either plexin alone, suggesting that SEMA3A and SEMA3F signals, even though both essential, are partially redundant.
Science | 2014
K. Bercsenyi; Nathalie Schmieg; J. B. Bryson; M. Wallace; Paola Caccin; Matthew Golding; Giuseppe Zanotti; Linda Greensmith; R. Nischt; Giampietro Schiavo
Tetanus neurotoxin (TeNT) is among the most poisonous substances on Earth and a major cause of neonatal death in nonvaccinated areas. TeNT targets the neuromuscular junction (NMJ) with high affinity, yet the nature of the TeNT receptor complex remains unknown. Here, we show that the presence of nidogens (also known as entactins) at the NMJ is the main determinant for TeNT binding. Inhibition of the TeNT-nidogen interaction by using small nidogen-derived peptides or genetic ablation of nidogens prevented the binding of TeNT to neurons and protected mice from TeNT-induced spastic paralysis. Our findings demonstrate the direct involvement of an extracellular matrix protein as a receptor for TeNT at the NMJ, paving the way for the development of therapeutics for the prevention of tetanus by targeting this protein-protein interaction. Preventing nidogen-tetanus toxin interaction at the neuromuscular junction can protect mice from tetanus-induced spastic paralysis. A potential peptide to prevent tetanus? Tetanus (TeNT) and botulinum (BoNT) neurotoxins represent a family of powerful bacterial protein toxins that cause tetanus and botulism in humans and animals. The molecular mechanisms responsible for the entry and axonal retrograde transport of these toxins have been the subject of intense research. However, tetanus and botulism remain incurable, at least in part because of their high-affinity binding to synapses. Although the receptors for BoNT have recently been characterized at the molecular level, no protein receptor for TeNT at the neuromuscular junction has been identified. Bercsenyi et al. now suggest that TeNT exploits nidogen-1 and -2 for its binding to motor neurons. This binding is required for TeNTs internalization and axonal retrograde transport. Nidogens are extracellular matrix proteins that engage in multiple protein-protein interactions essential for the integrity of several tissues, including the nervous system. Interfering with the interaction between nidogens and TeNT by administering short nidogen-derived peptides blocked toxin binding to the neuromuscular junction and protected mice from tetanus. Science, this issue p. 1118
The EMBO Journal | 2014
Marco Terenzio; Matthew Golding; Matthew R G Russell; Krzysztof B Wicher; Ian Rosewell; Bradley Spencer-Dene; David Ish-Horowicz; Giampietro Schiavo
We have identified a new function for the dynein adaptor Bicaudal D homolog 1 (BICD1) by screening a siRNA library for genes affecting the dynamics of neurotrophin receptor‐containing endosomes in motor neurons (MNs). Depleting BICD1 increased the intracellular accumulation of brain‐derived neurotrophic factor (BDNF)‐activated TrkB and p75 neurotrophin receptor (p75NTR) by disrupting the endosomal sorting, reducing lysosomal degradation and increasing the co‐localisation of these neurotrophin receptors with retromer‐associated sorting nexin 1. The resulting re‐routing of active receptors increased their recycling to the plasma membrane and altered the repertoire of signalling‐competent TrkB isoforms and p75NTR available for ligand binding on the neuronal surface. This resulted in attenuated, but more sustained, AKT activation in response to BDNF stimulation. These data, together with our observation that Bicd1 expression is restricted to the developing nervous system when neurotrophin receptor expression peaks, indicate that BICD1 regulates neurotrophin signalling by modulating the endosomal sorting of internalised ligand‐activated receptors.
Frontiers in Cellular Neuroscience | 2014
Marco Terenzio; Matthew Golding; Giampietro Schiavo
Neurons rely on the long-range transport of several signaling molecules such as neurotrophins and their receptors, which are required for neuronal development, function and survival. However, the nature of the machinery controlling the trafficking of signaling endosomes containing activated neurotrophin receptors has not yet been completely elucidated. We aimed to identify new players involved in the dynamics of neurotrophin signaling endosomes using a medium-throughput unbiased siRNA screening approach to quantify the intracellular accumulation of two fluorescently tagged reporters: the binding fragment of tetanus neurotoxin (HCT), and an antibody directed against the neurotrophin receptor p75NTR. This screen performed in motor neurons differentiated from mouse embryonic stem (ES) cells identified a number of candidate genes encoding molecular motors and motor adaptor proteins involved in regulating the intracellular trafficking of these probes. Bicaudal D homolog 1 (BICD1), a molecular motor adaptor with pleiotropic roles in intracellular trafficking, was selected for further analyses, which revealed that BICD1 regulates the intracellular trafficking of HCT and neurotrophin receptors and likely plays an important role in nervous system development and function.
Genes & Development | 2002
Christiana Ruhrberg; Holger Gerhardt; Matthew Golding; Rose Watson; Sofia Ioannidou; Hajime Fujisawa; Christer Betsholtz; David T. Shima
Investigative Ophthalmology & Visual Science | 2004
Tomohiko Usui; Susumu Ishida; Kenji Yamashiro; Yuichi Kaji; V. Poulaki; Johnny Moore; Tara Moore; Shiro Amano; Yoshitaka Horikawa; Darlene A. Dartt; Matthew Golding; David T. Shima; Anthony P. Adamis